Zhengye Biotechnology Holding Limited(ZYBT)
Search documents
美股异动丨利邦厨具跌50.93%,为跌幅最大的中概股




Ge Long Hui· 2025-09-26 00:37
Core Viewpoint - Chinese concept stocks experienced significant declines, with the top five losers showing steep drops in their stock prices. Group 1: Stock Performance - Libang Kitchenware (LBGJ) fell by 50.93%, closing at 0.660, with a decrease of 0.685 and a trading volume of 3.6995 million [1] - Zhengye Biological (ZYBT) dropped by 39.64%, ending at 3.000, down by 1.970, with a trading volume of 8.2297 million [1] - Reaya Electronics (RAYA) decreased by 33.05%, closing at 0.0476, down by 0.0235, with a trading volume of 3.9496 million [1] - Xiao i Robot (AIXI) saw a decline of 23.21%, closing at 1.290, down by 0.390, with a trading volume of 1.4258 million [1] - Easy Electric (EZGO) fell by 16.08%, ending at 0.1879, down by 0.0360, with a trading volume of 0.9919 million [1]
美股异动丨正业生物跌19.98%,为跌幅最大的中概股
Ge Long Hui· 2025-09-24 01:02
中概股收盘跌幅前五的个股为:正业生物跌19.98%,铭腾国际跌19.53%,安高盟跌17.27%,迦里仕人 才跌16.29%,虎虎科技跌15.51%。(格隆汇) (原标题:美股异动丨正业生物跌19.98%,为跌幅最大的中概股) ...
美股异动丨闽东红涨35.33%,为涨幅最大的中概股



Ge Long Hui· 2025-09-16 00:37
Group 1 - The top five gainers among Chinese concept stocks include: Mindonghong with a rise of 35.33%, Pitanium up by 21.27%, Heitong Technology increasing by 17.07%, Zhengye Biology rising 14.7%, and Mint up 14.24% [1] - Mindonghong (ORIS) closed at 0.1827 with a gain of 35.33%, translating to an increase of 0.0477 and a trading volume of 13.18 million [1] - Pitanium (PTNM) reached a price of 7.240, marking a 21.27% increase, which is an addition of 1.270 with a trading volume of 9.68 million [1] Group 2 - Heitong Technology (DKI) saw its stock price rise to 8.300, reflecting a 17.07% increase, equivalent to a gain of 1.210 and a trading volume of 4.25 million [1] - Zhengye Biology (ZYBT) closed at 10.690, with a 14.70% increase, amounting to a rise of 1.370 and a trading volume of 2.35 million [1] - Mint (MIMI) ended at 10.750, showing a 14.24% increase, which is an increase of 1.340 with a trading volume of 39.62 million [1]
美股异动丨707 Cayman Holdings跌65.81%,为跌幅最大的中概股




Ge Long Hui· 2025-09-04 00:29
Group 1 - The top five Chinese concept stocks that experienced the largest declines at closing were: 707 Cayman Holdings down 65.81%, MoBe down 33.33%, Deep Fan Lian down 23.78%, Zhengye Biology down 23.02%, and Hongyao Digital Technology down 22.76% [1][1][1] Group 2 - 707 Cayman Holdings had a latest price of 0.759 with a decline of 1.461 and a trading volume of 29.17 million [1][1][1] - MoBe's latest price was 0.0002, down by 0.0001 with a trading volume of 0.00024 million [1][1][1] - Deep Fan Lian's latest price was 0.3026, down by 0.0944 with a trading volume of 0.1519 million [1][1][1] - Zhengye Biology's latest price was 9.750, down by 2.915 with a trading volume of 4.3126 million [1][1][1] - Hongyao Digital Technology's latest price was 1.120, down by 0.330 with a trading volume of 1.3085 million [1][1][1]
美股异动丨禄达技术涨62.6%,为涨幅最大的中概股
Ge Long Hui· 2025-09-03 00:27
Group 1 - The top five gainers among Chinese concept stocks include Luda Technology with a rise of 62.6%, Zhengye Biology with 35.31%, Xiangsong International with 31.87%, AirNet Technology with 28.77%, and Cheche Technology with 24.68% [1] - Luda Technology's latest price is 9.870, with a gain of 3.800 and a trading volume of 9.4865 million [1] - Zhengye Biology's latest price is 12.665, with a gain of 3.305 and a trading volume of 2.9232 million [1] Group 2 - Xiangsong International's latest price is 2.255, with a gain of 0.545 and a trading volume of 4.2776 million [1] - AirNet Technology's latest price is 5.550, with a gain of 1.240 and a trading volume of 2.31 million [1] - Cheche Technology's latest price is 1.1100, with a gain of 0.2197 and a trading volume of 2.9753 million [1]
正业生物上涨17.05%,报8.17美元/股,总市值3.87亿美元
Jin Rong Jie· 2025-08-25 17:49
8月26日,正业生物(ZYBT)盘中上涨17.05%,截至01:34,报8.17美元/股,成交82.38万美元,总市值 3.87亿美元。 财务数据显示,截至2024年12月31日,正业生物收入总额1.86亿人民币,同比减少11.95%;归母净利润 1131.1万人民币,同比减少64.04%。 资料显示,正业生物控股有限公司是一家在开曼群岛注册成立的境外控股母公司,主要通过其境内实体 子公司吉林正业生物制品股份有限公司运营。其子公司主要专注于兽医疫苗的研究、开发、制造和销 售,重点是中华人民共和国的牲畜疫苗。 本文源自:金融界 作者:行情君 ...
美股异动丨星际时尚跌54.05%,为跌幅最大的中概股




Ge Long Hui· 2025-08-22 00:27
Group 1 - The article highlights the significant decline in the stock prices of several Chinese concept stocks, with the largest drop being 54.05% for Star Fashion [1] - Other notable declines include FunPlus at 40.21%, Rongzhi Group at 30.34%, Zhengye Bio at 29.4%, and AirNet Technology at 26.91% [1] - The trading volumes for these stocks varied, with Star Fashion having a trading volume of 4.2523 million, while FunPlus had 1.5189 million [1]
正业生物上涨2.33%,报7.777美元/股,总市值3.69亿美元
Jin Rong Jie· 2025-08-20 15:07
8月20日,正业生物(ZYBT)盘中上涨2.33%,截至22:43,报7.777美元/股,成交1.33万美元,总市值3.69 亿美元。 财务数据显示,截至2024年12月31日,正业生物收入总额1.86亿人民币,同比减少11.95%;归母净利润 1131.1万人民币,同比减少64.04%。 资料显示,正业生物控股有限公司是一家在开曼群岛注册成立的境外控股母公司,主要通过其境内实体 子公司吉林正业生物制品股份有限公司运营。其子公司主要专注于兽医疫苗的研究、开发、制造和销 售,重点是中华人民共和国的牲畜疫苗。 本文源自:金融界 作者:行情君 ...
正业生物上涨4.23%,报7.827美元/股,总市值3.71亿美元
Jin Rong Jie· 2025-08-18 18:15
Core Viewpoint - Zhengye Biology (ZYBT) experienced a stock price increase of 4.23%, reaching $7.827 per share, with a total market capitalization of $371 million as of August 19 [1] Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company was 11.311 million RMB, showing a significant year-on-year decline of 64.04% [1] Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]
正业生物上涨3.17%,报7.8美元/股,总市值3.70亿美元
Jin Rong Jie· 2025-08-13 13:53
Core Insights - Zhengye Biological (ZYBT) opened with a 3.17% increase, trading at $7.80 per share, with a total market capitalization of $370 million [1] - The company reported total revenue of 186 million RMB for the year ending December 31, 2024, representing a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company was 11.31 million RMB, reflecting a significant year-on-year decline of 64.04% [1] Company Overview - Zhengye Biological Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]